These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 19418657)

  • 1. Maturation inhibitors as new antiretroviral agents.
    Richards J; McCallister S
    J HIV Ther; 2008 Dec; 13(4):79-82. PubMed ID: 19418657
    [No Abstract]   [Full Text] [Related]  

  • 2. Maturation inhibitors: a new therapeutic class targets the virus structure.
    Salzwedel K; Martin DE; Sakalian M
    AIDS Rev; 2007; 9(3):162-72. PubMed ID: 17982941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecule of the month. PA-457.
    Drug News Perspect; 2004 May; 17(4):283. PubMed ID: 15334176
    [No Abstract]   [Full Text] [Related]  

  • 4. Drug evaluation: bevirimat--HIV Gag protein and viral maturation inhibitor.
    Temesgen Z; Feinberg JE
    Curr Opin Investig Drugs; 2006 Aug; 7(8):759-65. PubMed ID: 16955688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PA-457, new kind of antiretroviral: ten-day clinical trial results.
    James JS
    AIDS Treat News; 2005 Aug; (414):7-8. PubMed ID: 16206398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study may point way forward for bevirimat.
    Proj Inf Perspect; 2008 Dec; (47):11. PubMed ID: 19227562
    [No Abstract]   [Full Text] [Related]  

  • 7. Novel targets for anti-retroviral therapy.
    Bhattacharya S; Osman H
    J Infect; 2009 Dec; 59(6):377-86. PubMed ID: 19815027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. S-1360 Shionogi-GlaxoSmithKline.
    Billich A
    Curr Opin Investig Drugs; 2003 Feb; 4(2):206-9. PubMed ID: 12669383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can the further clinical development of bevirimat be justified?
    Wainberg MA; Albert J
    AIDS; 2010 Mar; 24(5):773-4. PubMed ID: 20154583
    [No Abstract]   [Full Text] [Related]  

  • 10. [Prediction of the efficacy of bevirimat used for the treatment of HIV infection in Russia].
    Kazennova EV; Vasil'ev AV; Bobkova MR
    Vopr Virusol; 2010; 55(3):37-41. PubMed ID: 20608080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [CCR5 antagonists: a new class of antiretrovirals].
    Peytavin G; Calvez V; Katlama C
    Therapie; 2009; 64(1):9-16. PubMed ID: 19463248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Report from the 2008 joint ICAAC/IDSA meeting. Bevirimat: predictors of response.
    Sax PE
    AIDS Clin Care; 2008 Dec; 20(12):104. PubMed ID: 19274775
    [No Abstract]   [Full Text] [Related]  

  • 13. The maturation inhibitor bevirimat (PA-457) can be active in patients carrying HIV type-1 non-B subtypes and recombinants.
    Yebra G; Holguín A
    Antivir Ther; 2008; 13(8):1083-5. PubMed ID: 19195334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Integrase inhibition].
    Bogner JR
    MMW Fortschr Med; 2009 Apr; 151(18):68-71. PubMed ID: 19769082
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase I evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254, a next-generation HIV-1 maturation inhibitor.
    Joshi SR; Fernando D; Igwe S; McKenzie L; Krishnatry AS; Halliday F; Zhan J; Greene TJ; Xu J; Ferron-Brady G; Lataillade M; Min S
    Pharmacol Res Perspect; 2020 Dec; 8(6):e00671. PubMed ID: 33200887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New developments in HIV drug resistance.
    Cane PA
    J Antimicrob Chemother; 2009 Sep; 64 Suppl 1():i37-40. PubMed ID: 19675018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New developments in natural products-based anti-AIDS research.
    Yu D; Morris-Natschke SL; Lee KH
    Med Res Rev; 2007 Jan; 27(1):108-32. PubMed ID: 16888749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new assault on HIV.
    Stix G
    Sci Am; 2006 Jun; 294(6):76-9. PubMed ID: 16711363
    [No Abstract]   [Full Text] [Related]  

  • 19. New CCR5 antagonist enters phase II trials. Drug would be first-line therapy.
    AIDS Alert; 2008 Aug; 23(8):89-90. PubMed ID: 18724488
    [No Abstract]   [Full Text] [Related]  

  • 20. Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection.
    Martin DE; Salzwedel K; Allaway GP
    Antivir Chem Chemother; 2008; 19(3):107-13. PubMed ID: 19024627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.